glp 1 dangers The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 GLP-1 and Low Blood Pressure:

The attorneys general identified the following concerns including: Counterfeit semaglutide imported from China, Turkey and India and repackaged as FDA-approved products Online sellers promoting research-only peptides while providing instructions for human injection Consumers mixing raw powders at home, leading to overdoses, contamination and serious adverse events Compounding pharmacies operating around legal boundaries, including insanitary conditions and high-impurity formulations Risks of hospitalization tied to dosing errors and adulterated ingredients The attorneys general asked the FDA and the Department of Homeland Security to take joint action to intercept illegal imports and protect patient safety

Initial animal studies and studies of other GLP-1 medications have shown an increased risk of thyroid cancer, which has prompted a warning of the potential side effect to patients prescribed GLP-1 medications

We Have Epic

A pilot study of exenatide actions in Alzheimers disease

Natural GLP-1 has a half-life of about two minutes